Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 86689 refers to a confirmatory test for antibodies against human T-lymphotropic virus type I (HTLV-I), human T-lymphotropic virus type II (HTLV-II), or human immunodeficiency virus (HIV) types I and II. This test is crucial for diagnosing infections caused by these viruses, which are known to be sexually transmitted and can also be transmitted through unscreened blood, shared needles, or from mother to child during pregnancy or breastfeeding. HTLV-I and HTLV-II are associated with serious health conditions, including disorders of the bone marrow and blood cells, with HTLV-I specifically linked to adult T-cell leukemia. HIV, on the other hand, compromises the immune system by targeting and destroying CD4 T cells, which are essential for the body’s defense against infections. The progression of HIV can lead to acquired immunodeficiency syndrome (AIDS), the most severe stage of the infection. The testing process typically begins with an enzyme immunoassay (EIA) to detect the presence of antibodies in a blood sample. If the EIA yields a positive result, a confirmatory test is conducted using the Western blot method, which is a more specific immunoassay technique that separates proteins based on size and shape, allowing for the identification of antibodies to HTLV-I, HTLV-II, HIV-I, or HIV-II. This confirmatory testing is essential for accurate diagnosis and subsequent management of these viral infections.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The confirmatory test represented by CPT® Code 86689 is indicated for the following conditions:

  • HTLV-I Infection Confirmation of antibodies in patients suspected of being infected with human T-lymphotropic virus type I.
  • HTLV-II Infection Confirmation of antibodies in patients suspected of being infected with human T-lymphotropic virus type II.
  • HIV Infection Confirmation of antibodies in patients suspected of being infected with human immunodeficiency virus types I or II.

2. Procedure

The procedure for CPT® Code 86689 involves several critical steps to ensure accurate detection of antibodies. Initially, a blood sample is collected from the patient, which is then subjected to an enzyme immunoassay (EIA). This initial screening test is designed to detect the presence of antibodies specific to HTLV-I, HTLV-II, or HIV-I and HIV-II in the serum or plasma. If the EIA test returns a positive result, indicating the potential presence of these antibodies, a confirmatory test is performed. This confirmatory testing is conducted using the Western blot method, which is a highly specific immunoassay technique. In this step, multiple samples, including a control containing known HIV-I or HIV-II proteins, are placed side-by-side on a gel matrix. An electrical current is applied, causing the proteins to migrate through the gel, effectively separating them based on their size and shape. Following this separation, the proteins are transferred onto a thin membrane, where the patient’s sample is introduced. If antibodies to HTLV-I, HTLV-II, HIV-I, or HIV-II are present, they will bind to the corresponding proteins on the membrane. To visualize these interactions, labeled antibodies are used, allowing for the detection of the virus. The results of the test are then compared against known negative and positive control samples to confirm the presence of antibodies.

3. Post-Procedure

After the confirmatory testing associated with CPT® Code 86689, patients may receive their results within a specified timeframe, which can vary based on the laboratory's processing capabilities. It is essential for healthcare providers to discuss the results with the patient, including the implications of a positive or negative test outcome. In the case of a positive result, further counseling and management strategies should be implemented to address the patient's health needs and potential treatment options. Additionally, patients may be advised on preventive measures to reduce the risk of transmission to others. Follow-up testing may also be necessary to monitor the patient's health status and response to any treatment initiated.

Short Descr HTLV/HIV CONFIRMJ ANTIBODY
Medium Descr ANTIBODY HTLV/HIV ANTIBODY CONFIRMATORY TEST
Long Descr Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 235 - Other Laboratory
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GA Waiver of liability statement issued as required by payer policy, individual case
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
GZ Item or service expected to be denied as not reasonable and necessary
Date
Action
Notes
2013-01-01 Changed Short Descriptor changed.
1990-01-01 Added First appearance in code book in 1990.
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"